- COVID-19
- Biosimilars
- Cataract Therapeutics
- DME
- Gene Therapy
- Workplace
- Ptosis
- Optic Relief
- Imaging
- Geographic Atrophy
- AMD
- Presbyopia
- Ocular Surface Disease
- Practice Management
- Pediatrics
- Surgery
- Therapeutics
- Optometry
- Retina
- Cataract
- Pharmacy
- IOL
- Dry Eye
- Understanding Antibiotic Resistance
- Refractive
- Cornea
- Glaucoma
- OCT
- Ocular Allergy
- Clinical Diagnosis
- Technology
DME treatment gains marketing authorization in Italy
The Italian Medicines Agency has granted marketing authorization to Alimera Sciences’ sustained-release intravitreal implant (Iluvien) for the treatment of chronic diabetic macular edema (DME).
Atlanta-The Italian Medicines Agency has granted marketing authorization to Alimera Sciences’ sustained-release intravitreal implant (Iluvien) for the treatment of chronic diabetic macular edema (DME).
The Italian authorization is the seventh national approval in the European Union, preceded by Austria, the United Kingdom, Portugal, France, Germany, and Spain.
The treatment is commercially available in the United Kingdom and Germany.
Designed as a C class product in Italy, the treatment will be available initially to private paying patients. Alimera is currently pursuing H Class designation with the Italian regulatory authorities, which, if granted, would expand patient access to the product.
For more articles in this issue of Ophthalmology Times eReport, click here.
To receive weekly clinical news and updates in ophthalmology, subscribe to the Ophthalmology Times eReport.
